Dabrafenib plus trametinib provides clinically important response rates in BRAF-mutated gliomas
1. Response to treatment was noted in 33% of the high-grade glioma cohort and 69% of the low-grade cohort. 2. ...
Tag: BRAF inhibitor
Vemurafenib plus rituximab associated with complete response in refractory hairy-cell leukemia
1. Vemurafenib plus rituximab treatment was associated with complete response for refractory or relapsed hairy-cell leukemia patients. 2. Post hoc ...
#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH
Click to read the study in the European Journal of Cancer.
#VisualAbstract: BRAF and MEK inhibitor combination therapy shows efficacy for advanced melanoma in Japanese patients
Click to read the study in the European Journal of Cancer.
#VisualAbstract: BRAF/MEK inhibitor therapy may be associated with risk of uveitis in patients with advanced melanoma
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Prognosis for advanced melanoma has improved between 2013 to 2017 for patients in the Netherlands
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Low plasma ctDNA may be predictive of better survival outcomes in patients with melanoma receiving first-line immune checkpoint inhibitors
Click to read the study in Clinical Cancer Research
#VisualAbstract: Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) ...